Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial

JACC: Heart Failure

Volumn 5, Issue 7, 2017, Pages 471-482

  Solomon, Scott D ^a   Rizkala, Adel R ^b   Gong, Jianjian ^b   Wang, Wenyan ^b   Anand, Inder S ^c   Ge, Junbo ^d   Lam, Carolyn S P ^e   Maggioni, Aldo P ^f   Martinez, Felipe ^g   Packer, Milton ^h   Pfeffer, Marc A ^a   Pieske, Burkert ^i,j   Redfield, Margaret M ^k   Rouleau, Jean L ^l   Van Veldhuisen, Dirk J ^m   Zannad, Faiez ⁿ   Zile, Michael R ^o,p   Desai, Akshay S ^a   Shi, Victor C ^b   Lefkowitz, Martin P ^b   McMurray, John J V ^q   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c UNIVERSITY OF MINNESOTA   (United States)

^d FUDAN UNIVERSITY   (China)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^f ANMCO RESEARCH CENTER   (Italy)

^g UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

^h BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

ⁱ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^j DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^k MAYO CLINIC   (United States)

^l MONTREAL HEART INSTITUTE   (Canada)

^m UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

ⁿ UNIVERSITÉ DE LORRAINE   (France)

^o MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^p RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^q UNIVERSITY OF GLASGOW   (United Kingdom)

more..

Author keywords

angiotensin receptor neprilysin inhibitor; heart failure with preserved ejection fraction; sacubitril; valsartan

Indexed keywords

MEMBRANE METALLOENDOPEPTIDASE; SACUBITRIL PLUS VALSARTAN; VALSARTAN; AMINOBUTYRIC ACID DERIVATIVE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; TETRAZOLE DERIVATIVE;

CARDIOVASCULAR RESPONSE; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ESTIMATED GLOMERULAR FILTRATION RATE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INCIDENCE; KIDNEY FAILURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; COMBINATION DRUG THERAPY; DOUBLE BLIND PROCEDURE; HEART FAILURE; PROCEDURES;

AMINOBUTYRATES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN RECEPTOR ANTAGONISTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; HEART FAILURE; HUMANS; NEPRILYSIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TETRAZOLES; TREATMENT OUTCOME; VALSARTAN;

EID: 85021807254     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2017.04.013     Document Type: Review

References (32)

1. Fonarow, G.C., Stough, W.G., Abraham, W.T., et al., for the OPTIMIZE-HF Investigators and Hospitals. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol 50 (2007), 768–777.
2. Lam, C.S., Donal, E., Kraigher-Krainer, E., Vasan, R.S., Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur J Heart Fail 13 (2011), 18–28.
3. Butler, J., Fonarow, G.C., Zile, M.R., et al. Developing therapies for heart failure with preserved ejection fraction: current state and future directions. J Am Coll Cardiol HF 2 (2014), 97–112.
4. Zile, M.R., Baicu, C.F., Biomarkers of diastolic dysfunction and myocardial fibrosis: application to heart failure with a preserved ejection fraction. J Cardiovasc Transl Res 6 (2013), 501–515.
5. Kraigher-Krainer, E., Shah, A.M., Gupta, D.K., et al., for the PARAMOUNT Investigators. Impaired systolic function by strain imaging in heart failure with preserved ejection fraction [published correction appears in J Am Coll Cardiol 2014;64:335]. J Am Coll Cardiol 63 (2014), 447–456.
6. Shah, A.M., Claggett, B., Sweitzer, N.K., et al. Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation 132 (2015), 402–414.
7. Borlaug, B.A., Lam, C.S., Roger, V.L., Rodeheffer, R.J., Redfield, M.M., Contractility and ventricular systolic stiffening in hypertensive heart disease insights into the pathogenesis of heart failure with preserved ejection fraction. J Am Coll Cardiol 54 (2009), 410–418.
8. Shah, S.J., Kitzman, D.W., Borlaug, B.A., et al. Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap. Circulation 134 (2016), 73–90.
9. Yusuf, S., Pfeffer, M.A., Swedberg, K., et al., for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362 (2003), 777–781.
10. Cleland, J.G., Tendera, M., Adamus, J., et al., for the PEP-CHF Investigators. The Perindopril in Elderly People With Chronic Heart Failure (PEP-CHF) study. Eur Heart J 27 (2006), 2338–2345.
11. Massie, B.M., Carson, P.E., McMurray, J.J., et al., for the I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 359 (2008), 2456–2467.
12. Pitt, B., Pfeffer, M.A., Assmann, S.F., et al., for the TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370 (2014), 1383–1392.
13. Ponikowski, P., Voors, A.A., Anker, S.D., et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC): developed with the special contribution of the Heart Failure Association (HFA) of the ESC [published correction appears in Eur Heart J 2017:ehx158]. Eur Heart J 37 (2016), 2129–2200.
14. Redfield, M.M., Heart failure with preserved ejection fraction. N Engl J Med 375 (2016), 1868–1877.
15. Vardeny, O., Miller, R., Solomon, S.D., Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure. J Am Coll Cardiol HF 2 (2014), 663–670.
16. McMurray, J.J., Packer, M., Desai, A.S., et al., for the PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371 (2014), 993–1004.
17. McKie, P.M., Schirger, J.A., Costello-Boerrigter, L.C., et al. Impaired natriuretic and renal endocrine response to acute volume expansion in pre-clinical systolic and diastolic dysfunction. J Am Coll Cardiol 58 (2011), 2095–2103.
18. Lee, D.I., Zhu, G., Sasaki, T., et al. Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease. Nature 519 (2015), 472–476.
19. van Heerebeek, L., Hamdani, N., Falcão-Pires, I., et al. Low myocardial protein kinase G activity in heart failure with preserved ejection fraction. Circulation 126 (2012), 830–839.
20. McKie, P.M., Burnett, J.C. Jr., NT-proBNP: the gold standard biomarker in heart failure. J Am Coll Cardiol 68 (2016), 2437–2439.
21. Solomon, S.D., Zile, M., Pieske, B., et al., for the Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) Investigators. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 380 (2012), 1387–1395.
22. Lin, D.W., Wei, L.J., Yang, I., Ying, Z., Semiparametric regression for the mean and rate functions of recurrent events. J R Statist Soc B 62 (2000), 711–730.
23. Andersen, P.K., Gill, R.D., Cox's regression model for counting processes: a large sample study. Ann Statist 10 (1982), 1100–1120.
24. Cowling, B.J., Hutton, J.L., Shaw, J.E.H., Joint modeling of event counts and survival times. Appl Statist 55:Part 1 (2006), 31–39.
25. Bretz, F., Maurer, W., Brannath, W., Posch, M., A graphical approach to sequentially rejective multiple test procedures. Stat Med 28 (2009), 586–604.
26. Pfeffer, M.A., Claggett, B., Assmann, S.F., et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation 131 (2015), 34–42.
27. Zile, M.R., Gottdiener, J.S., Hetzel, S.J., et al., for the I-PRESERVE Investigators. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation 124 (2011), 2491–2501.
28. Shah, A.M., Shah, S.J., Anand, I.S., et al., for the TOPCAT Investigators. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Circ Heart Fail 7 (2014), 104–115.
29. Rogers, J.K., Pocock, S.J., McMurray, J.J., et al. Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved [published correction appears in Eur J Heart Fail 2014;16:592]. Eur J Heart Fail 16 (2014), 33–40.
30. Langenickel, T.H., Tsubouchi, C., Ayalasomayajula, S., et al. The effect of LCZ696 (sacubitril/valsartan) on amyloid-β concentrations in cerebrospinal fluid in healthy subjects. Br J Clin Pharmacol 81 (2016), 878–890.
31. Cannon, J.A., Shen, L., Jhund, P.S., et al., PARADIGM-HF Investigators and Committees. Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction. Eur J Heart Fail 19 (2017), 129–137.
32. Pandharipande, P.P., Girard, T.D., Jackson, J.C., et al., for the BRAIN-ICU Study Investigators. Long-term cognitive impairment after critical illness. N Engl J Med 369 (2013), 1306–1316.